Get the Stockscreener App
14.46
0.00%
0.00
After Hours:
14.46
Amicus Therapeutics Inc stock is traded at $14.46, with a volume of 4.45M.
It is up +0.00% in the last 24 hours and up +0.63% over the past month.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$14.46
Open:
$14.47
24h Volume:
4.45M
Relative Volume:
0.86
Market Cap:
$4.54B
Revenue:
$634.21M
Net Income/Loss:
$-27.11M
P/E Ratio:
-163.39
EPS:
-0.0885
Net Cash Flow:
$29.85M
1W Performance:
-0.07%
1M Performance:
+0.63%
6M Performance:
+79.85%
1Y Performance:
+115.18%
1-Day Range:
$14.45
$14.47
1-Week Range:
$14.45
$14.48
52-Week Range:
$5.51
$14.48
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.46 | 4.54B | 634.21M | -27.11M | 29.85M | -0.0885 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Downgrade | Jefferies | Buy → Hold |
| Dec-29-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-22-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-17-25 | Initiated | Citigroup | Buy |
| Sep-18-25 | Upgrade | Needham | Hold → Buy |
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Institution Moves: Can Amicus Therapeutics Inc expand its profit marginsEarnings Overview Summary & Capital Efficient Trading Techniques - baoquankhu1.vn
Amicus Therapeutics Hits New 52-Week High of $14.47 - Markets Mojo
How does Amicus Therapeutics Inc score in quality rankings2026 Biggest Moves & Community Shared Stock Ideas - baoquankhu1.vn
Patterns Watch: Will Amicus Therapeutics Inc benefit from geopolitical trendsPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
(FOLD) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Amicus Therapeutics Hits New 52-Week High of $14.48 - Markets Mojo
Panic Selling: Is Amicus Therapeutics Inc showing insider buyingWeekly Market Outlook & Daily Technical Forecast Reports - baoquankhu1.vn
Gap Down: Will Amicus Therapeutics Inc benefit from geopolitical trendsBuy Signal & Reliable Momentum Entry Alerts - baoquankhu1.vn
Will Amicus Therapeutics Inc benefit from geopolitical trends2026 Dividend Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
Amicus Therapeutics stock hits 52-week high at 14.46 USD By Investing.com - Investing.com Australia
Amicus Therapeutics stock hits 52-week high at 14.46 USD - Investing.com
FOLD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Amicus Therapeutics (NASDAQ:FOLD) Hits New 1-Year HighTime to Buy? - MarketBeat
BioMarin Pharmaceutical Secures European Regulatory Approval for Amicus Therapeutics Acquisition - marketscreener.com
EU Commission OKs BioMarin's Sole Acquisition of Amicus Therapeutics - marketscreener.com
Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Technical Analysis & Stock Price Forecast - intellectia.ai
Amicus Therapeutics stock hits 52-week high at $14.44 By Investing.com - Investing.com South Africa
Amicus Therapeutics stock hits 52-week high at $14.44 - Investing.com
EPS Watch: Is Amicus Therapeutics Inc in a bullish channelMarket Sentiment Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 1-Year HighStill a Buy? - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After A Strong 71% One Year Total Return - Yahoo Finance
210,800 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by CIBRA Capital Ltd - MarketBeat
FOLD PE Ratio & Valuation, Is FOLD Overvalued - intellectia.ai
Recap Report: What is the long term forecast for Amicus Therapeutics Inc stockQuarterly Market Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Vanguard disaggregates holdings, reports 0% in Amicus (NASDAQ: FOLD) - Stock Titan
JPMorgan Chase & Co. Sells 94,105 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
ETFs investiert in Amicus Therapeutics, Inc.-Aktien - TradingView
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion - MSN
Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week HighWhat's Next? - MarketBeat
Amicus Therapeutics stock hits 52-week high at 14.39 USD By Investing.com - Investing.com Canada
Amicus Therapeutics stock hits 52-week high at 14.39 USD - Investing.com
Hudson Bay Capital Management LP Cuts Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Amicus Therapeutics, Inc.(NasdaqGM: FOLD) dropped from NASDAQ Biotechnology Index - marketscreener.com
FOLD Should I Buy - Intellectia AI
872,411 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by Ion Asset Management Ltd. - MarketBeat
Iron Triangle Partners LP Takes Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin to acquire rare disease drug developer Amicus for $4.8B - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside - Yahoo Finance
Amicus Therapeutics stock hits 52-week high at 14.38 USD By Investing.com - Investing.com Nigeria
Elevation Point Wealth Partners LLC Makes New Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Strong Recent Share Price Momentum - simplywall.st
Amicus Therapeutics, Inc. $FOLD Shares Sold by Prosight Management LP - MarketBeat
Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) After Strong One Year Share Price Performance - simplywall.st
Amicus Therapeutics stock hits 52-week high at 14.38 USD - Investing.com India
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):